Based on our current findings, we suggest osteopontin as a promising therapeutic target in ischemic stroke and specifically suggest anti-ostepontin antibody as a novel adjunctive therapeutic in acute ischemic stroke and potentially other CNS diseases associated with neurovascular unit and blood–brain barrier dysfunction (Fig. 6). Here, SPP1 is linked to ischemic stroke.